Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096746 · ClinicalTrials.gov registry record
Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 200
- Enrollment target
NCT00096746: Completed study, sponsored by Bristol-Myers Squibb.
NCT00096746 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096746 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequently receiving PI-containing therapy.
Interventions
- DRUG LPV/RTV + 2NRTIs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-09 |
What the finished NCT00096746 record still lists
NCT00096746 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which LPV/RTV + 2NRTIs is the first listed.
NCT00096746 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096746 about?
NCT00096746 is a clinical study titled "Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects". This study will compare the response of subjects who failed a first-line ATV-containing regimen and who have the 150L-containing virus to subsequent protease inhibitor (PI)-containing therapy with that of a cohort who has failed a first-line reverse transcriptase inhibitor (NNRTI), and is subsequent...
What is the current status of trial NCT00096746?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2004-11. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00096746?
The interventions under investigation include: LPV/RTV + 2NRTIs (DRUG).
Who is sponsoring clinical trial NCT00096746?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia